OCS logo

OCS Oculis Holding AG

NASDAQ Global Market · Biotechnology · Healthcare

$7.40
+0.01 (+0.13%)

Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye. A key asset in its therapeutic portfolio is OCS-01, a topical formulation of dexamethasone, currently progressing through Phase 3 clinical trials for the man…

Market Cap: $456.80Moculis.com

Price

No data yet.

Social Signal Score

45
5d
—
30d
48
7 mentions
—
60d
42
18 mentions
—
90d
45
21 mentions
—
news: 21

Analyst Ratings

9 analysts
Buyconsensus
Strong Buy 0Buy 9Hold 0Sell 0Strong Sell 0
Avg price target$36.75+396.6%
Low $26Median $38High $45
Current Consensus

Revenue

$7.0K
$0.00$87.0K$174.0K$261.0K
Sep 2021Sep 2026

Analyst Estimates

FY2025
$-1.77
$-2.00–$-1.40
8 analysts
FY2026
$-1.40
$-1.60–$-1.24
6 analysts
FY2027
$-1.52
$-1.87–$-1.28
6 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Riad Sherif
Sector
Healthcare
Industry
Biotechnology
Employees
60
Beta
0.23
Country
CH
Piotroski score
2 / 9 (Weak)
Altman Z-score
6.99
oculis.com